Benzgalantamine for Alzheimer's and Traumatic Brain Injury: What Caregivers Need to Know

Benzgalantamine is a newly FDA-approved medication for Alzheimer's disease that is also being studied for traumatic brain injury (TBI). This article explains what benzgalantamine is, how it works, and why it may be relevant for someone with both Alzheimer's and a history of TBI. We'll cover the current research, practical considerations for caregivers in a long-term care facility, and what to discuss with your loved one's healthcare team. While the drug is not yet approved for TBI, early research shows promise, and understanding this can help you have informed conversations with clinicians.

Key points

• Benzgalantamine is a newly FDA-approved acetylcholinesterase inhibitor for Alzheimer's, available as a sublingual tablet for easier administration.
• Preclinical studies show benzgalantamine reduces toxic tau protein and preserves brain function after TBI in animal models, but human trials are not yet underway.
• The drug is not approved for TBI; any use for this purpose would be off-label and should be discussed thoroughly with a clinician.
• Caregivers should monitor for side effects like nausea, dizziness, and falls, and coordinate closely with facility staff.
• Avoid combining benzgalantamine with medications that impair memory or balance, such as benzodiazepines or anticholinergics.
• Staying informed about clinical trials and maintaining open communication with the healthcare team are key to optimizing care.

What Is Benzgalantamine and How Does It Work?

Benzgalantamine is a medication that belongs to a class of drugs called acetylcholinesterase inhibitors. These drugs work by increasing levels of a brain chemical called acetylcholine, which is important for memory and learning. In Alzheimer's disease, brain cells that produce acetylcholine are damaged, leading to memory loss and cognitive decline. By blocking the enzyme that breaks down acetylcholine, benzgalantamine helps maintain higher levels of this chemical, potentially slowing symptom progression. The drug was developed as a reformulation of galantamine, designed to be taken as a sublingual (under the tongue) rapidly dissolving tablet. This is particularly important for people who have difficulty swallowing, which is common after a traumatic brain injury.

Why Is Benzgalantamine Being Studied for Traumatic Brain Injury?

Traumatic brain injury (TBI) is a major public health issue, with about one million emergency room visits each year in the United States, though many cases go unreported. People with TBI often experience long-term cognitive problems, including memory loss, difficulty concentrating, and mood changes. Interestingly, TBI is a known risk factor for developing Alzheimer's disease later in life. Researchers have found that a protein called hyperphosphorylated tau, which builds up in the brains of people with Alzheimer's, also accumulates after repeated mild TBIs. In animal studies, benzgalantamine has shown the ability to reduce this toxic tau protein and preserve brain function after both single and repetitive mild TBIs. The drug is currently in preclinical stages for TBI, meaning it has not yet been tested in humans for this condition, but the results are promising enough that the developers plan to approach the FDA later this year to begin clinical trials.

What Does This Mean for a Person with Alzheimer's and a History of TBI?

If your loved one has Alzheimer's disease and also has a history of traumatic brain injury, benzgalantamine may be particularly relevant. The same pathological processes—tau protein buildup, inflammation, and cholinergic dysfunction—are involved in both conditions. While benzgalantamine is currently only FDA-approved for Alzheimer's, its potential to address both conditions simultaneously is exciting. However, it's important to remember that the TBI research is still in early stages. For now, the drug is only available for Alzheimer's, and any use for TBI would be off-label. Caregivers should discuss with the healthcare team whether benzgalantamine might be appropriate, especially if the person has swallowing difficulties that make the sublingual formulation advantageous.

General caregiving information, not medical advice. Check medications and major care changes with your clinician.

Discuss with your clinician

Ask whether benzgalantamine is appropriate given the person's specific Alzheimer's stage and TBI history.

Inquire about potential drug interactions with other medications the person is taking, especially those affecting heart rate, bladder function, or sleep.

Discuss the risks and benefits of using benzgalantamine off-label for TBI, as it is not yet FDA-approved for this indication.

Ask about the possibility of participating in a clinical trial for benzgalantamine in TBI if the person is interested.

Clarify the dosing schedule and what to do if a dose is missed or if side effects occur.

Request a review of all current medications to identify any that might worsen cognition or increase fall risk, such as benzodiazepines or anticholinergics.

Related guides

• FDA-Approved Medications for Alzheimer's Disease: A Practical Guide for Caregivers and Early-Stage Patients
• Anticholinergic Alert: Why Common Medications Can Worsen Dementia & What to Do
• Does chronic insomnia raise dementia risk?
• Medication-assisted treatment for alcohol use disorder
• Fall prevention when dementia impairs safety awareness
• Medication Safety: A Step-by-Step Guide to Preventing Errors and Adverse Reactions
• Communication with care home staff during emergencies
• Building a medication routine for a person with dementia
• Alzheimer's pathology basics: amyloid plaques and tau tangles

Sources

• All Home Care Matters
• Dementia Careblazers
• The Dementia Doctor
• NW GWEC
• Alzheimer's Proof